Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens / 부인종양
Journal of Gynecologic Oncology
;
: e16-2018.
Article
in English
| WPRIM
| ID: wpr-740168
ABSTRACT
OBJECTIVE:
Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established.METHODS:
Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3–6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined.RESULTS:
A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0% vs. 77.6%; p=0.410) and OS (84.6% vs. 84.3%; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ≤50 years of age who received the CP (p50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ≤50 years of age in the CP group; and p=0.061 for patients ≤50 years of age in the PT group). Patients with the CP or PT regimen for 3–5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050).CONCLUSION:
Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Ovarian Neoplasms
/
Platinum
/
Taiwan
/
Chemotherapy, Adjuvant
/
Paclitaxel
/
Disease-Free Survival
/
Cyclophosphamide
/
Drug Therapy
/
National Health Programs
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Journal of Gynecologic Oncology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS